The first paper that I would like to point out to Neuropenews readers has attracted my attention because it concerns a very general therapeutical and social problem, that is the costs of drugs, and the choice between a “brand” drug and its “generic” counterpart. It is a “perspective” paper, published on the 13 November issue of the New England J of Medicine, by Jonathan D. Alpers, William M. Stauffer & Aaron S. Kesselheim ( NEJM, 2014; 371;1859-1862) : “High-Cost Generic Drugs – Implications for Patients and Policymakers”. This paper refers mainly to USA and FDA problems and initiatives. However, I feel deeply in my gut that these problems will pretty soon affect European countries too.
Tag